PolyPid’s D-PLEX100 Gets FDA Fast Track | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20065917

Show notes

PolyPid’s D-PLEX100 just got a major boost: the FDA accepted its application with Priority Review status, slashing review time to a November 2026 target, and they’ve teamed up with Azurity Pharmaceuticals for U.S. and Canadian commercialization — a deal worth over $290 million in milestones. This move signals strong regulatory confidence and sets the stage for a fast patient launch, while PolyPid also eyes Europe and expanding surgical uses, all backed by solid manufacturing readiness and enough cash to fund operations through 2028. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/338abe47d49db45b

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.